Cargando…

Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial(†)

AIMS: This multicentre, randomized trial compared three strategies of AF ablation: ablation of complex fractionated electrograms (CFE) alone, pulmonary vein isolation (PVI) alone, and combined PVI + CFE ablation, using standardized automated mapping software. METHODS AND RESULTS: Patients with drug-...

Descripción completa

Detalles Bibliográficos
Autores principales: Verma, Atul, Mantovan, Roberto, Macle, Laurent, De Martino, Guiseppe, Chen, Jian, Morillo, Carlos A., Novak, Paul, Calzolari, Vittorio, Guerra, Peter G., Nair, Girish, Torrecilla, Esteban G., Khaykin, Yaariv
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2878965/
https://www.ncbi.nlm.nih.gov/pubmed/20215126
http://dx.doi.org/10.1093/eurheartj/ehq041
_version_ 1782181898889461760
author Verma, Atul
Mantovan, Roberto
Macle, Laurent
De Martino, Guiseppe
Chen, Jian
Morillo, Carlos A.
Novak, Paul
Calzolari, Vittorio
Guerra, Peter G.
Nair, Girish
Torrecilla, Esteban G.
Khaykin, Yaariv
author_facet Verma, Atul
Mantovan, Roberto
Macle, Laurent
De Martino, Guiseppe
Chen, Jian
Morillo, Carlos A.
Novak, Paul
Calzolari, Vittorio
Guerra, Peter G.
Nair, Girish
Torrecilla, Esteban G.
Khaykin, Yaariv
author_sort Verma, Atul
collection PubMed
description AIMS: This multicentre, randomized trial compared three strategies of AF ablation: ablation of complex fractionated electrograms (CFE) alone, pulmonary vein isolation (PVI) alone, and combined PVI + CFE ablation, using standardized automated mapping software. METHODS AND RESULTS: Patients with drug-refractory, high-burden paroxysmal (episodes >6 h, >4 in 6 months) or persistent atrial fibrillation (AF) were enrolled at eight centres. Patients (n = 100) were randomized to one of three arms. For CFE alone (n = 34), spontaneous/induced AF was mapped using validated, automated CFE software and all sites <120 ms were ablated until AF termination/non-inducibility. For PVI (n = 32), all four PV antra were isolated and confirmed using a circular catheter. For PVI + CFE (n = 34), all four PV antra were isolated, followed by AF induction and ablation of all CFE sites until AF termination/non-inducibility. Patients were followed at 3, 6, and 12 months with a visit, ECG, 48 h Holter. Atrial fibrillation symptoms were confirmed by loop recording. Repeat procedures were allowed within the first 6 months. The primary endpoint was freedom from AF >30 s at 1 year. Patients (age 57 ± 10 years, LA size 42 ± 6 mm) were 35% persistent AF. In CFE, ablation terminated AF in 68%. Only 0.4 PVs per patient were isolated as a result of CFE. In PVI, 94% had all four PVs successfully isolated. In PVI + CFE, 94% had all four PVs isolated, 76% had inducible AF with additional CFE ablation, with 73% termination of AF. There were significantly more repeat procedures in the CFE arm (47%) vs. PVI (31%) or PVI + CFE (15%) (P = 0.01). After one procedure, PVI + CFE had a significantly higher freedom from AF (74%) compared with PVI (48%) and CFE (29%) (P = 0.004). After two procedures, PVI + CFE still had the highest success (88%) compared with PVI (68%) and CFE (38%) (P = 0.001). Ninety-six percent of these patients were off anti-arrhythmics. Complications were two tamponades, no PV stenosis, and no mortality. CONCLUSION: In high-burden paroxysmal/persistent AF, PVI + CFE has the highest freedom from AF vs. PVI or CFE alone after one or two procedures. Complex fractionated electrogram alone has the lowest one and two procedure success rates with a higher incidence of repeat procedures. ClinicalTrials.gov identifier number NCT00367757.
format Text
id pubmed-2878965
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-28789652010-06-02 Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial(†) Verma, Atul Mantovan, Roberto Macle, Laurent De Martino, Guiseppe Chen, Jian Morillo, Carlos A. Novak, Paul Calzolari, Vittorio Guerra, Peter G. Nair, Girish Torrecilla, Esteban G. Khaykin, Yaariv Eur Heart J Clinical Research AIMS: This multicentre, randomized trial compared three strategies of AF ablation: ablation of complex fractionated electrograms (CFE) alone, pulmonary vein isolation (PVI) alone, and combined PVI + CFE ablation, using standardized automated mapping software. METHODS AND RESULTS: Patients with drug-refractory, high-burden paroxysmal (episodes >6 h, >4 in 6 months) or persistent atrial fibrillation (AF) were enrolled at eight centres. Patients (n = 100) were randomized to one of three arms. For CFE alone (n = 34), spontaneous/induced AF was mapped using validated, automated CFE software and all sites <120 ms were ablated until AF termination/non-inducibility. For PVI (n = 32), all four PV antra were isolated and confirmed using a circular catheter. For PVI + CFE (n = 34), all four PV antra were isolated, followed by AF induction and ablation of all CFE sites until AF termination/non-inducibility. Patients were followed at 3, 6, and 12 months with a visit, ECG, 48 h Holter. Atrial fibrillation symptoms were confirmed by loop recording. Repeat procedures were allowed within the first 6 months. The primary endpoint was freedom from AF >30 s at 1 year. Patients (age 57 ± 10 years, LA size 42 ± 6 mm) were 35% persistent AF. In CFE, ablation terminated AF in 68%. Only 0.4 PVs per patient were isolated as a result of CFE. In PVI, 94% had all four PVs successfully isolated. In PVI + CFE, 94% had all four PVs isolated, 76% had inducible AF with additional CFE ablation, with 73% termination of AF. There were significantly more repeat procedures in the CFE arm (47%) vs. PVI (31%) or PVI + CFE (15%) (P = 0.01). After one procedure, PVI + CFE had a significantly higher freedom from AF (74%) compared with PVI (48%) and CFE (29%) (P = 0.004). After two procedures, PVI + CFE still had the highest success (88%) compared with PVI (68%) and CFE (38%) (P = 0.001). Ninety-six percent of these patients were off anti-arrhythmics. Complications were two tamponades, no PV stenosis, and no mortality. CONCLUSION: In high-burden paroxysmal/persistent AF, PVI + CFE has the highest freedom from AF vs. PVI or CFE alone after one or two procedures. Complex fractionated electrogram alone has the lowest one and two procedure success rates with a higher incidence of repeat procedures. ClinicalTrials.gov identifier number NCT00367757. Oxford University Press 2010-06 2010-03-09 /pmc/articles/PMC2878965/ /pubmed/20215126 http://dx.doi.org/10.1093/eurheartj/ehq041 Text en Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2010. For permissions please email: journals.permissions@oxfordjournals.org http://creativecommons.org/licenses/by-nc/2.0/uk/ The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org.
spellingShingle Clinical Research
Verma, Atul
Mantovan, Roberto
Macle, Laurent
De Martino, Guiseppe
Chen, Jian
Morillo, Carlos A.
Novak, Paul
Calzolari, Vittorio
Guerra, Peter G.
Nair, Girish
Torrecilla, Esteban G.
Khaykin, Yaariv
Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial(†)
title Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial(†)
title_full Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial(†)
title_fullStr Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial(†)
title_full_unstemmed Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial(†)
title_short Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial(†)
title_sort substrate and trigger ablation for reduction of atrial fibrillation (star af): a randomized, multicentre, international trial(†)
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2878965/
https://www.ncbi.nlm.nih.gov/pubmed/20215126
http://dx.doi.org/10.1093/eurheartj/ehq041
work_keys_str_mv AT vermaatul substrateandtriggerablationforreductionofatrialfibrillationstarafarandomizedmulticentreinternationaltrial
AT mantovanroberto substrateandtriggerablationforreductionofatrialfibrillationstarafarandomizedmulticentreinternationaltrial
AT maclelaurent substrateandtriggerablationforreductionofatrialfibrillationstarafarandomizedmulticentreinternationaltrial
AT demartinoguiseppe substrateandtriggerablationforreductionofatrialfibrillationstarafarandomizedmulticentreinternationaltrial
AT chenjian substrateandtriggerablationforreductionofatrialfibrillationstarafarandomizedmulticentreinternationaltrial
AT morillocarlosa substrateandtriggerablationforreductionofatrialfibrillationstarafarandomizedmulticentreinternationaltrial
AT novakpaul substrateandtriggerablationforreductionofatrialfibrillationstarafarandomizedmulticentreinternationaltrial
AT calzolarivittorio substrateandtriggerablationforreductionofatrialfibrillationstarafarandomizedmulticentreinternationaltrial
AT guerrapeterg substrateandtriggerablationforreductionofatrialfibrillationstarafarandomizedmulticentreinternationaltrial
AT nairgirish substrateandtriggerablationforreductionofatrialfibrillationstarafarandomizedmulticentreinternationaltrial
AT torrecillaestebang substrateandtriggerablationforreductionofatrialfibrillationstarafarandomizedmulticentreinternationaltrial
AT khaykinyaariv substrateandtriggerablationforreductionofatrialfibrillationstarafarandomizedmulticentreinternationaltrial